Policy | April 20, 2021
Indian pharma industry registers 18% exports growth: Narendra Modi
Essential medicines were made available to more than 150 countries around the world during the pandemic
Essential medicines were made available to more than 150 countries around the world during the pandemic
On a full-year basis, revenue from operations for FY26 grew 18.9 percent year-on-year to Rs 827.87 crore compared to Rs 696.48 crore in FY25
PAT soars 201%, EBITDA up 88% on strong PHPO demand & margin expansion
Growth driven by strong performance across Sugar Free, RiteBite Max Protein, Everyuth, Glucon-D and Nutralite portfolios
US formulations grew 11% to Rs. 564 crore as Alembic enters US branded pharmaceuticals market with launch of Pivya
Strong export-led growth and improved profitability as the company focuses on CNS drug development and global regulatory footprint
With robust FY26 growth, plans AI-led diagnostics and genomic testing expansion
FY26 revenue rises 17% to Rs. 5,453 crore as US generics business jumps 49% and adjusted EBITDA margin improves to 26% for the quarter
Pharma major reports FY26 revenue of Rs 9,204 crore with 16.6% growth
Fresenius Kabi's approved generic therapy addresses acute symptomatic hypocalcemia and targets a US market valued at nearly $71 million
Subscribe To Our Newsletter & Stay Updated
